This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Balleine, R. L. Articles by Meltzer, P. S. Search for Related Content PubMed PubMed Citation Articles by Balleine, R. L. Articles by Meltzer, P. S.

Molecular Grading of Ductal Carcinoma In situ of the Breast

Authors' Affiliations: ¹ Translational Oncology Sydney West Area Health Service; ² Westmead Institute for Cancer Research; ³ Westmead Millennium Institute; ⁴ University of Sydney; ⁵ Tissue Pathology, Institute of Clinical Pathology and Medical Research, Westmead, New South Wales, Australia; ⁶ Genetics Branch, National Cancer Institute, Bethesda, Maryland; ⁷ Department of Pathology, Anatomy, and Cell Biology and ⁸ Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; and ⁹ Department of Pathology, Health Network Laboratories/Lehigh Valley Hospital, Allentown, Pennsylvania

Requests for reprints: Paul S. Meltzer, Genetics Branch, National Cancer Institute, 37 Convent Drive, MSC 4265, Room 6138, Bethesda, MD 20892-4265. Phone: 301-496-5266; Fax: 301-480-3281; E-mail: pmeltzer{at}mail.nih.gov.

Purpose: Increased incidence of ductal carcinoma in situ (DCIS) associated with mammographic screening for breast cancer has emphasized the challenges of managing this condition. The aim of this study was to identify informative clinical indicators of DCIS biology by molecular profiling.

Experimental Design: Areas of in situ carcinoma, atypical ductal hyperplasia, and benign epithelium were microdissected from 46 invasive breast cancers. Oligonucleotide probes showing differential expression between DCIS associated with grade 1 and 3 invasive cancer were identified by microarray-based gene expression profiling. Expression at these probes was used to define a "molecular grade" subcategorization of all samples. The genomic basis of molecular grade was examined by array-based comparative genomic hybridization. Clinical course was examined in a cohort of 134 patients with DCIS treated by surgery alone.

Results: DCIS samples were designated as low or high molecular grade based on expression at 173 probes. The low molecular grade subgroup included low (n = 10) and intermediate (n = 11) nuclear grade DCIS as well as all samples of atypical ductal hyperplasia (n = 4) and benign epithelium (n = 7). The high molecular grade subgroup included DCIS of intermediate (n = 7) and high (n = 19) nuclear grade. The character and degree of genomic aberration were distinct between molecular grade subgroups. A classification tree model including nuclear grade and Ki67 score accurately predicted molecular grade for 95.7% of samples. In an independent cohort, this showed a pattern of rapid disease recurrence for high molecular grade DCIS.

Conclusions: Molecular profiling indicates a binary grading scheme for DCIS. This practical approach has potential to improve clinical evaluation of DCIS.